India Immune-Oncology Drugs Market Is Forecasted To Witness A Thriving Growth By 2026

Press Release

Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Request For a Sample Copy of This Business Report : https://www.coherentmarketinsights.com/insight/request-sample/2631

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immuno-Oncology Drugs market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.

Increasing Incidences of Cancer Cases and Introduction of Novel Immuno-Oncology Therapies is expected to Drive Growth of the India Immune-Oncology Drugs Market

Rising incidences of cancer in India is expected to boost the immuno-oncology drugs market during the forecast period. For instance, according to Indian Council of Medical Research (ICMR) – National Institute of Cancer Prevention and Research (NICPR), incidence of breast cancer is 25.8 per 100,000 women in 2018 and is expected to reach 35 per 100,000 women in 2026.

India Immune-Oncology Drugs Market – Competitive Landscape

Key players operating in the India Immune-Oncology Drugs market include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy’s Laboratories Ltd., Bristol – Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology Company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.

Purchase This Premium Report : https://www.coherentmarketinsights.com/insight/buy-now/2631

Detailed Segmentation:

  • India Immuno-Oncology Drugs Market, By Drug Type:
    • Immune Checkpoint Inhibitors
      • Nivolumab (Opdivo)
      • Atezolimumab (Tecentriq)
      • Pembrolizumab (Keytruda)
      • Durvalumab (Imfinzi)
    • Monoclonal Antibodies
      • Rituximab (Rituxan)
      • Trastazumab (Herceptin)
      • Bevacizumab (Avastin)
      • Nimotuzumab (Biomab EGFR)
      • Pertuzumab (Perjeta)
      • Ado-Trastuzumab Emtansine (Kadcyla)
    • Cancer Vaccines
      • Gardasil
      • Cervarix
  • India Immuno-Oncology Drugs Market, By Cancer Type:
    • Lung Cancer
    • Blood Cancer
    • Breast Cancer
    • Ovarian Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Stomach Cancer
    • Head & Neck Cancer
    • Others
  • Company Profiles
    • Amgen, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Hoffmann-La Roche AG
    • Intas Pharmaceuticals Ltd.
    • AstraZeneca plc
    • Mylan N.V.
    • Reddy’s Laboratories
    • Bristol – Myers Squibb
    • Merck & Co., Inc.
    • BIOCAD-Biotechnology company
    • Reliance Life Sciences
    • Biocon Limited
    • Hetero Drugs Limited

India Immune-Oncology Drugs Market – Restraints

Major restraining factors for India Immune-Oncology Drugs Market include inadequate delivery of affordable and equitable cancer care drugs in India, which hampers the India immune-oncology drugs market. For instance, according to the data published in Lancet Journal in 2014, public expenditure on cancer in India remains below US$ 10 per person (compared to over US$ 100 per person in high-income or developed countries) and overall public expenditure on healthcare is still only slightly above 1% of the gross domestic product. According to the same source, out-of-pocket payments, which account for over three-quarter of cancer expenditures in India are one of the greatest threats to patients and families. Moreover, higher effectiveness of cancer drugs and comparatively less availability of better alternative results restricts key players to drive down cost of cancer drugs.